Elshazli Rami M, Toraih Eman A, Hussein Mohammad H, Ruiz Emmanuelle M, Kandil Emad, Fawzy Manal S
Department of Biochemistry and Molecular Genetics, Faculty of Physical Therapy, Horus University-Egypt, New Damietta 34517, Egypt.
Endocrine and Oncology Division, Department of Surgery, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Cancers (Basel). 2023 Jan 4;15(2):338. doi: 10.3390/cancers15020338.
Single nucleotide polymorphisms in genes involved in microRNA processing/maturation and release may deregulate the microRNAome expression levels. We aimed to assess the relationship between miRNA machinery genetic variants and human cancer risk using integrative bioinformatics analyses to identify the role of these genes in cancer aggressiveness. Mutations of 8176 pan-cancer samples were retrieved from 33 studies in "TCGA" database, and a Cox regression model for survival was performed. Next, 22 computationally identified variants within 11 genes were selected based on their high citation rate and MAF. Relevant articles through March 2020 were included. Pooled estimates under the five genetic association models were calculated. Publication bias and heterogeneity between articles were evaluated. Trial Sequential Analysis (TSA) was applied to assess the power and reliability of the draw conclusions. TCGA patients with different cancer types revealed significant alterations in miRNA machinery genes, with mutation frequency ranging from 0.6-13% of samples. RAN was associated with LN metastasis, while TARBP2 and PIWIL1 gene mutations exhibited better overall survival. In the meta-analysis, 45 articles (74,593 cases and 89,198 controls) met the eligibility criteria. Pooled analysis revealed an increased cancer risk with DROSHArs10719G, RANrs3803012G, DGCR8rs417309A, and GEMIN3rs197414A. In contrast, both DICER1rs1057035T and GEMIN4rs2743048G conferred protection against developing cancer. TSA showed the cumulative evidence is inadequate, and the addition of further primary studies is necessary. This study suggests a potential role of miRNA biogenesis genes in cancer development/prognosis. Further functional studies may reveal biological explanations for the differential risks of the machinery variants in different cancer types.
参与微小RNA加工/成熟和释放的基因中的单核苷酸多态性可能会使微小RNA组的表达水平失调。我们旨在通过综合生物信息学分析评估微小RNA机制基因变异与人类癌症风险之间的关系,以确定这些基因在癌症侵袭性中的作用。从“TCGA”数据库的33项研究中检索了8176个泛癌样本的突变情况,并进行了生存的Cox回归模型分析。接下来,基于11个基因中22个经计算鉴定的变异的高引用率和小等位基因频率进行选择。纳入截至2020年3月的相关文章。计算了五种遗传关联模型下的合并估计值。评估了文章之间的发表偏倚和异质性。应用序贯试验分析(TSA)来评估得出结论的效力和可靠性。不同癌症类型的TCGA患者显示微小RNA机制基因有显著改变,突变频率在样本的0.6%-13%之间。RAN与淋巴结转移相关,而TARBP2和PIWIL1基因突变表现出更好的总生存期。在荟萃分析中,45篇文章(74593例病例和89198例对照)符合纳入标准。合并分析显示,携带DROSHArs10719G、RANrs3803012G、DGCR8rs417309A和GEMIN3rs197414A会增加患癌风险。相反,DICER1rs1057035T和GEMIN4rs2743048G都对患癌有保护作用。TSA显示累积证据不足,需要增加更多的原始研究。本研究表明微小RNA生物合成基因在癌症发生/预后中具有潜在作用。进一步的功能研究可能揭示不同癌症类型中机制变异的不同风险的生物学解释。